• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Clinical Investigator Warned for ClinicalTrials.gov Noncompliance

Clinical Investigator Warned for ClinicalTrials.gov Noncompliance

September 13, 2021

A Los Angeles doctor is the first individual investigator to receive an FDA warning letter for failing to report trial results to ClinicalTrials.gov, a violation that could result in thousands of dollars in fines, the letter said.

In an Aug. 31 letter, the agency warned Andrey Petrikovets that he had 30 days to submit to the ClinicalTrials.gov registry results of a phase 4 postoperative pain-relief trial he conducted at the University Hospitals Cleveland Medical Center. The trial concluded in June 2018 and the agency first notified Petrikovets of his noncompliance in a July 20, 2021, letter.

Petrikovets submitted the results to ClinicalTrials.gov one day after receiving the warning letter, sidestepping a potential fine of at least $10,000 for every day he was in noncompliance. According to the registry’s website, the information is currently undergoing quality control review before being posted.

The Petrikovets letter is the third such warning the FDA has given for noncompliance with ClinicalTrials.gov requirements. Previously, the agency cited two trial sponsors — Acceleron Pharma and Accuitis — for the same violation (CenterWatch Weekly, Aug. 23).

Read the warning letter at https://bit.ly/3C3n8Uz.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing